Skip to main content
TipRanks
Go Ultimate75% OFF

Polaryx Therapeutics, Inc. (PLYX) Stock Statistics & Valuation Metrics

24 Followers

Total Valuation

Polaryx Therapeutics, Inc. has a market cap or net worth of $75.27M. The enterprise value is $106.28T.

Market Cap
$75.27M
Enterprise Value
$106.28T

Share Statistics

Polaryx Therapeutics, Inc. has 49,845,993 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
49,845,993
Owned by Insiders
49.07%
Owned by Institutions
6.27%

Financial Efficiency

Polaryx Therapeutics, Inc.’s return on equity (ROE) is -1.97 and return on invested capital (ROIC) is -171.33%.

Return on Equity (ROE)
-1.97
Return on Assets (ROA)
-1.74
Return on Invested Capital (ROIC)
-171.33%
Return on Capital Employed (ROCE)
-1.71
Revenue Per Employee
0
Profits Per Employee
-816.82K
Employee Count
11
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Polaryx Therapeutics, Inc. is -7.35. Polaryx Therapeutics, Inc.’s PEG ratio is 0.08.

PE Ratio
-7.35
PS Ratio
0.00
PB Ratio
8.71
Price to FCF
-8.26
Price to Operating Cash Flow
-8.26
PEG Ratio
0.08

Income Statement

In the last 12 months, Polaryx Therapeutics, Inc. had revenue of 0 and earned -8.98M in profits. Earnings per share was -0.19.

Revenue
0
Gross Profit
0
Operating Income
-7.82M
Pretax Income
-8.98M
Net Income
-8.98M
EBITDA
-8.98M
Earnings Per Share (EPS)
-0.19

Cash Flow

In the last 12 months, operating cash flow was -8.02M and capital expenditures 0, giving a free cash flow of -8.02M billion.

Operating Cash Flow
-8.02M
Free Cash Flow
-8.02M
Free Cash Flow per Share
-0.16

Dividends & Yields

Polaryx Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-11.84%
Earnings Yield
-12.90%

Stock Price Statistics

Beta
0.35
52-Week Price Change
-96.20%
50-Day Moving Average
1.94
200-Day Moving Average
3.09
Relative Strength Index (RSI)
25.52
Average Volume (3m)
36.52K

Financial Position

Polaryx Therapeutics, Inc. as a current ratio of 8.55, with Debt / Equity ratio of 0.00%

Current Ratio
8.55
Quick Ratio
8.55
Debt to Market Cap
0.00
Net Debt to EBITDA
0.57
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Polaryx Therapeutics, Inc. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Polaryx Therapeutics, Inc. EV to EBITDA ratio is -6.79, with an EV/FCF ratio of -7.40.

EV to Sales
0.00
EV to EBITDA
-6.79
EV to Free Cash Flow
-7.40
EV to Operating Cash Flow
-7.40

Balance Sheet

Polaryx Therapeutics, Inc. has $8.44M in cash and marketable securities with $0.00 in debt, giving a net cash position of $8.44M billion.

Cash & Marketable Securities
$8.44M
Total Debt
$0.00
Net Cash
$8.44M
Net Cash Per Share
$0.17
Tangible Book Value Per Share
$0.15

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Polaryx Therapeutics, Inc. is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$10.00
Price Target Upside
651.88% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
-4.21%

Scores

Smart Score
3
AI Score
―